美股異動|思科盤前漲6.4% 勢創新高 第二財季業績超預期+150億回購計劃
思科(CSCO.US)盤前漲6.4%,報66.54美元,開盤後股價勢將創下新高。消息面上,思科公佈2025財年第二財季業績,銷售額同比增長9%至140億美元,好於分析師預期的139億美元;調整後每股收益爲0.94美元,好於分析師預期的0.91美元。遞延收入爲278億美元,同比增長8%。
展望2025財年,思科預計銷售額將介於560億至565億美元之間,較此前預期提高10億美元,略高於分析師預期的559.7億美元。此外,思科董事會批準了150億美元的股票回購計劃,股票回購的總規模將達到170億美元。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.